Abstract
Introduction Magnetic resonance imaging (MRI) enables direct measurements of muscle volume and quality, allowing for an in-depth understanding of their associations with anthropometric traits, and health conditions. However, it is unclear which muscle volume measurements: total muscle volume, regional measurements, measurements of muscle quality: intermuscular adipose tissue (IMAT) or proton density fat fraction (PDFF), are most informative and associate with relevant health conditions such as dynapenia and frailty.
Methods We developed a pipeline to automatically segment and extract image-derived phenotypes (IDPs) including total and regional muscle volumes and measures of muscle quality, and applied it to the neck-to-knee Dixon images in 44,520 UK Biobank participants. We further segmented paraspinal muscle from 2D quantitative MRI to quantify muscle PDFF and iron concentration. We defined dynapenia based on grip strength below sex-specific cut-off points and frailty based on five criteria. We used logistic regression to investigate the association between muscle volume and quality measurements and dynapenia and frailty.
Results Muscle volumes were significantly higher in male compared with female participants, even after correcting for height while, IMAT, (corrected for muscle volume) and paraspinal muscle PDFF were significantly higher in female compared with male participants. From the overall cohort, 7.6% (N = 3,261) were identified with dynapenia, and 1.1% (N = 455) with frailty. Dynapenia and frailty were positively associated with age and negatively associated with physical activity levels. In dynapenia, muscle volume IDPs were most informative, particularly total muscle exhibiting odds ratios (OR) of 0.392 and 95% confidence intervals (CI) = 0.361 - 0.426, while for frailty, muscle quality was found to be most informative, in particular thigh IMAT volume indexed to height squared (OR = 1.396, 95% CI = 1.374 - 1.418), both with p-values below the Bonferroni-corrected threshold (p < 8.6 × 10−5).
Conclusions Our fully automated method enables the quantification of muscle volumes and quality suitable for large population-based studies. For dynapenia, muscle volumes particularly those including greater body coverage such as total muscle are the most informative, whilst, for frailty, markers of muscle quality were the most informative IDPs. These results suggest that different measurements may have varying diagnostic values for different health conditions.
Competing Interest Statement
M.C., R.S, and E.P.S. are employees of Calico Life Sciences LLC. Y.L. is a former employee of Calico Life Sciences LLC. M.T., N.B., B.W., J.D.B. and E.L.T. declare no competing interests.
Funding Statement
This work was funded by Calico Life Sciences LLC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank has approval from the North West Multi-Centre Research Ethics Committee (REC reference: 11/NW/0382), and obtained written informed consent from all participants prior to the study. All methods were performed in accordance with the relevant guidelines and regulations as presented by the relevant authorities, including the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure 2 and 3 removed ann linear regression analysis is removed
